Welcome to our dedicated page for Biote news (Ticker: BTMD), a resource for investors and traders seeking the latest updates and insights on Biote stock.
Biote Corp. (BTMD) operates in the specialized field of hormone optimization, offering growth practice-building solutions. The company's primary focus is to empower Biote-certified practitioners with the tools and knowledge required to establish, build, and effectively implement hormone optimization programs. These programs are designed to provide personalized solutions tailored to individual patient needs.
Biote Corp. provides a comprehensive suite of components to its practitioners, including training, marketing support, and ongoing education. This holistic approach ensures that practitioners are well-equipped to deliver high-quality care in the hormone optimization space. The company's commitment to education and support is a key differentiator, enabling practitioners to stay at the forefront of this rapidly evolving field.
Recent achievements by Biote Corp. include expanding its network of certified practitioners and forging new partnerships aimed at enhancing its service offerings. The company continues to invest in research and development to improve its products and services, ensuring that they meet the highest standards of efficacy and safety.
Financially, Biote Corp. has demonstrated steady growth, driven by the increasing demand for hormone optimization solutions. The company's strategic initiatives and robust business model have positioned it well to capitalize on emerging opportunities in the healthcare sector.
For those interested in the latest updates and developments from Biote Corp., the company regularly releases news and updates, which are accessible through various channels.
Biote announced a successful case study involving a 54-year-old male patient with osteoporosis who achieved significant recovery after one year of testosterone pellet therapy. The therapy resulted in a notable increase in testosterone levels and improved bone density, enabling the patient to resume triathlon training. The findings, published in The Aging Male journal, highlight the potential benefits of sustained testosterone levels in treating osteoporosis and emphasize the need for more standardized treatment protocols. An estimated 10 million Americans over 50 have osteoporosis, underlining the impact of these findings on public health.
Biote Corp. (Nasdaq: BTMD), a leader in personalized hormone therapy, will participate in the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, CA. CEO Terry Weber and CFO Samar Kamdar will present on March 14 at 10:00 a.m. local time, alongside Chairman Marc Beer in investor meetings. Biote focuses on hormone optimization therapies, addressing a $7 billion global market, providing affordable solutions for symptoms related to hormone-related aging. Forward-looking statements in the release highlight potential risks and uncertainties regarding future performance.
Biote Corp. (NASDAQ: BTMD) announced it will release its fourth quarter and full year financial results on March 28, 2023, after market close. A conference call is scheduled for March 29, 2023, at 8:30 a.m. ET. Biote specializes in preventive health care through personalized hormone therapy and operates in a $7 billion global market for hormone-related aging conditions. Biote trains medical providers to identify and treat these conditions, aiming for enhanced patient outcomes and clinic success.
biote Corp. (NASDAQ: BTMD) has completed its underwritten public offering of 8.5 million shares of Class A common stock at $3.00 per share, including the exercise of underwriters’ option for 1.1 million shares. Notably, Biote is not receiving any proceeds from this offering, which was previously registered with the SEC. The offering is part of a strategic initiative to enhance market presence in the $7 billion hormone optimization market, delivering personalized health care through certified medical providers.
biote Corp. (NASDAQ: BTMD) announced a public offering of 7,391,305 shares of its Class A common stock at $3.00 per share, totaling approximately $22.17 million. The offering, set to close around January 9, 2023, involves selling stockholders, and the company will not receive proceeds from this transaction. Underwriters have a 30-day option to purchase an additional 1,108,695 shares. The registration statement was effective as of January 4, 2023, and the preliminary prospectus is available on the SEC's website.
Biote Corp. (Nasdaq: BTMD) has announced its participation in the Jefferies London Healthcare Conference from November 15-17, 2022. CEO Terry Weber will present on November 15, 2022, at 12:20 p.m. local time, followed by a Q&A session with CFO Samar Kamdar. A live audio webcast of the presentation will be available here. Biote specializes in personalized hormone therapy, targeting a $7 billion market in preventive healthcare.
Biote (NASDAQ: BTMD) announced strong third-quarter results for 2022, achieving $42 million in revenue, marking an 18% year-over-year increase. Despite a net loss of $(6.3) million and fully diluted GAAP EPS of $(1.74), adjusted EBITDA grew to $12.2 million, a 19% increase compared to the previous year. The company expects to meet the upper end of its guidance for annual revenue at $160-$166 million and adjusted EBITDA at $47-$51 million. The management highlighted ongoing expansion in sales and operations.
biote Corp. (Nasdaq: BTMD) has appointed Debby Morris to its Board of Directors, enhancing its focus on growth within the preventive health care sector. Morris brings over 30 years of financial leadership experience, previously serving as CFO at Apria, Inc., and in various executive roles. CEO Terry Weber emphasized her expertise will strengthen the Board as Biote implements its growth strategies in the $7 billion hormone optimization market. Morris expressed enthusiasm for contributing to Biote’s expansion and success.
biote Corp. (Nasdaq: BTMD) will release its third quarter financial results on November 8, 2022, post-market. A conference call to discuss these results is scheduled for November 9, 2022, at 8:30 a.m. ET. Biote focuses on preventive healthcare through personalized hormone therapies, addressing a $7 billion global market. The company trains medical practitioners to identify and treat symptoms of hormone-related aging conditions, enhancing clinic success.
Biote Corp. (Nasdaq: BTMD) has released an updated Corporate Presentation aimed at investors, available on the company's website. The presentation outlines Biote's growth in the hormone optimization space, emphasizing its franchise-like model that supports practitioners in establishing hormone therapy centers. The company focuses on training these practitioners to identify and treat hormone-related aging conditions. Investors are cautioned that forward-looking statements in the presentation carry risks, including market acceptance and regulatory challenges.
FAQ
What is the current stock price of Biote (BTMD)?
What is the market cap of Biote (BTMD)?
What does Biote Corp. do?
Who are Biote-certified practitioners?
What kind of support does Biote Corp. provide to practitioners?
What recent achievements has Biote Corp. made?
How does Biote Corp. ensure the quality of its hormone optimization solutions?
What is Biote Corp.'s financial condition?
How can I stay updated on Biote Corp.'s latest news?
What are the core components provided by Biote Corp. to practitioners?
Why is hormone optimization important?
Who can benefit from Biote Corp.'s hormone optimization programs?
